DiaMedica Therapeutics Stock Price, News & Analysis (NASDAQ:DMAC)

DiaMedica Therapeutics trades on the NASDAQ under the ticker symbol "DMAC."

DiaMedica Therapeutics Inc (NASDAQ:DMAC) posted its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.07. View DiaMedica Therapeutics' Earnings History.

DiaMedica Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for DiaMedica Therapeutics.

3 brokerages have issued 1-year price targets for DiaMedica Therapeutics' stock. Their forecasts range from $8.00 to $11.00. On average, they expect DiaMedica Therapeutics' stock price to reach $9.3333 in the next twelve months. This suggests a possible upside of 239.4% from the stock's current price. View Analyst Price Targets for DiaMedica Therapeutics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DiaMedica Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DiaMedica Therapeutics.

Headlines about DMAC stock have been trending somewhat negative on Saturday, according to InfoTrie. The research firm scores the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. DiaMedica Therapeutics earned a media sentiment score of -1.3 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for DiaMedica Therapeutics.

DiaMedica Therapeutics saw a increase in short interest during the month of August. As of August 31st, there was short interest totalling 12,600 shares, an increase of 16.7% from the July 31st total of 10,800 shares. Based on an average trading volume of 118,600 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.0% of the shares of the stock are sold short. View DiaMedica Therapeutics' Current Options Chain.

Some companies that are related to DiaMedica Therapeutics include Eton Pharmaceuticals (ETON), Fortress Biotech (FBIO), Scpharmaceuticals (SCPH), Avadel Pharmaceuticals (AVDL), Correvio Pharma (CORV), Menlo Therapeutics (MNLO), Chembio Diagnostics (CEMI), OASMIA PHARMACE/ADR (OASM), Galmed Pharmaceuticals (GLMD), Relmada Therapeutics (RLMD), Sesen Bio (SESN), Corvus Pharmaceuticals (CRVS), Savara (SVRA), Processa Pharmaceuticals (PCSA) and Avenue Therapeutics (ATXI).

Based on aggregate information from My MarketBeat watchlists, some companies that other DiaMedica Therapeutics investors own include Adamis Pharmaceuticals (ADMP), Alector (ALEC), Aptose Biosciences (APTO), Arcturus Therapeutics (ARCT), Aurinia Pharmaceuticals (AUPH), Baidu (BIDU), Capricor Therapeutics (CAPR), Cray (CRAY), Inovio Pharmaceuticals (INO) and Oracle (ORCL).

(DMAC) raised $18 million in an initial public offering on Friday, December 7th 2018. The company issued 4,000,000 shares at $4.00-$5.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO.

DiaMedica Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Granite Point Capital Management L.P. (1.92%), Worth Venture Partners LLC (1.11%), Eidelman Virant Capital (0.29%), Vanguard Group Inc. (0.29%) and BlackRock Inc. (0.23%). Company insiders that own DiaMedica Therapeutics stock include Dietrich John Pauls, Harry W Alcorn Jr, Randall Michael Giuffre, Richard D Pilnik and Scott Kellen. View Institutional Ownership Trends for DiaMedica Therapeutics.

DMAC stock was acquired by a variety of institutional investors in the last quarter, including Granite Point Capital Management L.P., Eidelman Virant Capital, Vanguard Group Inc., BlackRock Inc. and Worth Venture Partners LLC. Company insiders that have bought DiaMedica Therapeutics stock in the last two years include Dietrich John Pauls, Harry W Alcorn Jr, Randall Michael Giuffre, Richard D Pilnik and Scott Kellen. View Insider Buying and Selling for DiaMedica Therapeutics.

Shares of DMAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DMAC stock can currently be purchased for approximately $2.75.

DiaMedica Therapeutics has a market capitalization of $33.03 million and generates $500,000.00 in revenue each year. DiaMedica Therapeutics employs 9 workers across the globe.View Additional Information About DiaMedica Therapeutics.

The official website for DiaMedica Therapeutics is http://www.diamedica.com/.

DiaMedica Therapeutics' mailing address is 2 CARLSON PARKWAY SUITE 260, MINNEAPOLIS MN, 55447. The company can be reached via phone at 763-312-6755 or via email at [email protected]